Jaguar Health Inc SEC Filings

Jaguar Health, Inc. filed a Form D notice reporting a Regulation D exempt offering under Rule 506(b) for equity and related option/warrant securities. The filing lists a total offering amount of $1,000,000, with $1,000,000 sold and $0 remaining, indicating the offering has been fully sold. The notice records one investor as having invested and states the issuer accepts a minimum investment of $0. No sales commissions or finders’ fees were paid or estimated, and no proceeds were allocated to executive officers or directors. The filing identifies the issuer as a Delaware corporation with principal offices in San Francisco, California and is signed by Lisa A. Conte, President & CEO on 2025-10-10.

Jaguar Health, Inc. (JAGX) filed an S-3 shelf registration describing recent financings, intellectual property and product updates tied to its crofelemer franchise and related assets. The filing references a New Private Placement dated September 28, 2025 that issued New PIPE Shares and a Pre-Funded Warrant, and notes a concurrent private placement that closed on May 22, 2025 which included unregistered warrants to purchase 492,612 shares at an exercise price of $5.84 per share.

Clinical and commercial developments disclosed include ongoing investigator-initiated trials (IITs) and placebo-controlled studies of crofelemer for rare GI conditions, with initial Abu Dhabi IIT results showing reductions in total parenteral nutrition by up to 27% in an MVID patient and up to 12.5% in an SBS-IF patient. An abstract was accepted for presentation at NASPGHAN on November 5-8, 2025. The filing also notes that Canalevia-CA1 (crofelemer delayed-release tablets) is conditionally approved for chemotherapy-induced diarrhea in dogs and is commercially available through multiple US veterinary distributors. The document lists numerous certificates of designation for preferred stock series and describes exchange limits and beneficial ownership caps (commonly 19.99% limits) tied to Series N Preferred Stock and certain pre-funded warrants.

Jaguar Health, Inc. entered into a private placement with Brown Stone Capital Limited to issue securities on September 28, 2025. The company agreed to sell 161,583 shares of voting common stock and 479,442 pre-funded warrants exercisable for common stock. The Securities were offered under Rule 506 of Regulation D to an accredited investor. The filing includes a Securities Purchase Agreement and a Pre-Funded Warrant dated September 28, 2025, and is signed by CEO Lisa A. Conte on behalf of Jaguar Health.

Jaguar Health, Inc. (JAGX) filed a Form D Notice reporting a completed private equity offering under Rule 506(b) that raised $2,377,000. The filing identifies the issuer as a Delaware corporation with its principal place of business in San Francisco, CA. The offering sold all securities (Total Amount Sold: $2,377,000; Total Remaining to be Sold: $0) to a total of 15 investors. The minimum investment accepted was listed as $0. No sales commissions or finders' fees were reported, and no proceeds were allocated to named officers, directors or promoters.

Jaguar Health, Inc. filed an 8-K reporting a material event and attached corporate documents. The filing includes a Certificate of Designation of Preferences, Rights and Limitations of Series N Perpetual Preferred Stock, a Form of Securities Purchase Agreements, and an embedded Cover Page Interactive Data File within the inline XBRL document. The text defines a "Fundamental Transaction" to include transactions such as a sale, merger, consolidation, transfer of substantially all assets, sale or spin-off of subsidiaries, or any transaction where another person/group acquires more than 50% of outstanding common stock. The filing is signed by Lisa A. Conte, Chief Executive Officer & President and dated September 11, 2025.

Lincoln Alternative Strategies LLC filed a Form 3 reporting initial beneficial ownership in Jaguar Health, Inc. (JAGX). The filing states the reporting person holds 600,000 shares of Common Stock as a direct owner. The filing identifies the reporting persons relationship to the issuer as a Director and 10% owner. The statement is dated 08/28/2025 with a signature dated 08/29/2025.

Lincoln Alternative Strategies LLC disclosed ownership of 600,000 shares of Jaguar Health, Inc., representing 18.92% of the outstanding common stock based on 3,171,566 shares as of August 28, 2025. The filing shows Lincoln holds sole voting and sole dispositive power over all 600,000 shares. The Schedule 13G lists the issuer's and filer’s addresses and identifies the filer as a Delaware entity. The filer also certifies the shares were not acquired to change or influence control of the issuer.

Jaguar Health, Inc. held its 2025 Annual Meeting of Stockholders on August 19, 2025, where all seven proposals put to a vote were approved. The proposals were previously described in the company’s proxy statement.

Stockholders elected three directors to the board: James J. Bochnowski received 359,092 votes for and 21,757 withheld, Lisa A. Conte received 357,147 votes for and 23,702 withheld, and Jonathan B. Siegel received 361,236 votes for and 19,613 withheld; each director election had 425,060 broker non-votes. One proposal received 778,506 votes for, 13,484 against, and 13,919 abstentions, while several others each received over 321,000 votes for with 425,060 broker non-votes. The company also issued a press release summarizing these results, furnished as an exhibit.